Phase 2 Sickle Cell Disease Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 12 to 45 years who have any type of sickle cell disease (SCD), and who also have at least one of the following: a history of stroke or blood vessel problems (including silent brain changes in younger patients); repeated serious lung complications known as acute chest syndrome; repeated severe pain episodes that needed intravenous pain relief despite other treatments; a need for regular blood transfusions to prevent complications; or, for adult patients, a specific heart scan result showing abnormal blood flow through a valve (confirm with trial site for the exact measurement).
• People who have a close blood relative — a parent, brother, sister, or half-sibling — whose tissue type (HLA) is a half-match and who is willing and able to donate bone marrow.
• People who meet the institution's own health requirements for a bone marrow transplant procedure (confirm eligibility criteria with trial site).

Who may not be able to join:

• People who have a fully matched brother or sister who is willing and able to donate bone marrow.
• People with an uncontrolled infection, active tuberculosis, active Hepatitis B or C, or HIV.
• People who have previously had a bone marrow transplant or a solid organ transplant (such as a kidney or liver transplant).
• People who have had a brain surgery for blood vessel problems, a heart attack, a blood clot in the lungs, or a blood clot in a deep vein within the past 6 months.
• People currently taking medications that significantly affect how a drug called ruxolitinib is processed by the body.
• People with a known allergy or serious reaction to ruxolitinib or any other medication used in the treatment preparation process.
• People who are unable to swallow and keep down oral medication (note: feeding tubes may be permitted — confirm with trial site).
• People with a history of cancer, except for certain treated skin cancers or early-stage treated cancers (confirm with trial site).
• People who have participated in another clinical trial using an experimental or off-label drug or device in the past 3 months.
• People who are currently pregnant or breastfeeding.
• People with a significant autoimmune disease that is not well controlled.
• People with high levels of antibodies that could attack the donor's tissue type, unless reviewed and approved by the study's lead researcher.
• People, or in the case of younger participants their guardian, who are unwilling or unable to follow the study schedule, complete study assessments, sign the consent form, or use a highly effective form of contraception if applicable.
• People with any other condition that, in the treating doctor's judgement, could interfere with safe participation or with the study's results.

Important: Always verify eligibility with the trial site directly before applying.